Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII

Molecular Genetics and Metabolism

Volumn 101, Issue 4, 2010, Pages 370-382

  Bielicki, Julie ^a   McIntyre, Chantelle ^a,b   Anson, Donald S ^a,b  

^a Genetics and Molecular Pathology   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Central nervous system; Lentiviral vector; Mouse; Mucopolysaccharidoses

Indexed keywords

BETA GLUCURONIDASE; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GROWTH RETARDATION; HEARING IMPAIRMENT; INTELLECTUAL IMPAIRMENT; LENTIVIRINAE; LYSOSOME STORAGE DISEASE; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRIORITY JOURNAL; VISUAL DISORDER;

ANIMALS; ANTIBODIES; BETA-N-ACETYLHEXOSAMINIDASES; BRAIN; CELL LINE; EYE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLUCURONIDASE; GLYCOSAMINOGLYCANS; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENTRICULAR; INJECTIONS, INTRAVENOUS; LATERAL VENTRICLES; LENTIVIRUS; LYSOSOMES; MICE; MUCOPOLYSACCHARIDOSIS VII; URONIC ACIDS;

ANIMALIA; MURINAE; MUS;

EID: 78649325447     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2010.08.013     Document Type: Article

References (51)

1. Meikle P.J., Hopwood J.J., Claque A.F., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281(3):249-254.
2. Neufeld E.F., Muenzer J. The mucpolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 1995, 2465-2494. McGraw-Hill, New York. 7th edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
3. Rohrbach M., Clarke J.T. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007, 67(18):2697-2716.
4. Rovelli A.M. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant. 2008, 41(Suppl 2):S87-S89.
5. Sferra T.J., Backstorm K., Wang C., Rennard R., Miller M., Hu Y. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. 2004, 10(3):478-491.
6. McIntyre C., Derrick Roberts A.L., Ranieri E., Clements P.R., Byers S., Anson D.S. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 2008, 93(4):411-418.
7. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA 2005, 102(41):14777-14782.
8. Urayama A., Sly Grubb J.H., WS Banks W.A. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain-barrier. Proc. Natl Acad. Sci. USA 2004, 101(34):12658-12663.
9. Urayama A., Grubb J.H., Banks W.A., Sly W.S. Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc. Natl Acad. Sci. USA 2007, 104(31):12873-12878.
10. Frisella W.A., O'Connor L.H., Vogler C.A., Roberts M., Walkley S., Levy B., Daly T.M., Sands M.S. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther. 2001, 3(3):351-358.
11. Rudick R.A., Zirretta D.K., Herndon R.M. Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J. Neurosci. Methods. 1982, 6(3):253-259.
12. Huang T.Y., Chung H.W., Chen M.Y., Gilang L.H., Chin S.C., Lee C.S., Chen C.Y., Liu Y.J. Supratentorial cerebrospinal fluid production rate in healthy adults: quantification with two-dimensional cine phase-contrast MR imaging with high temporal and spatial resolution1. Radiology 2004, 233(2):603-608.
13. Han M.E., Kim H.J., Lee Y.S., Kim D.H., Choi J.T., Pan C.S., Yoon S., Baek S.Y., Kim B.S., Kim J.B., Oh S.O. Regulation of cerebrospinal fluid production by caffeine consumption. BMC Neurosci. 2009, 3(10):110.
14. Oshio K., Watanabe H., Song Y., Verkman A.S., Manley G.T. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1. FASEB J. 2005, 19(1):76-78.
15. Abbott N.J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem. Int. 2004, 45(4):545-552.
16. Fraldi A., Hemsley K., Crawley A., Lombardi A., Lau A., Sutherland L., Auricchio A., Ballabio A., Hopwood J.J. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum. Mol. Genet. 2007, 15(16):2693-2702.
17. Kwon E.J., Lasiene J., Jacobson B.E., Park I.K., Horner P.J., Pun S.H. Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone. Biomaterials 2010, 31(8):2417-2424.
18. Lee W.C., Tsoi Y., Troendle F.J., DeLucia M.W., Ahmed Z., Dicky C.A., Dickson D.W., Eckman C.B. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007, 21(10):2520-2527.
19. Passini M.A., Watson D., Vite C.H., Landsburg D.J., Feigenbaum A.L., Wolfe J.H. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 2003, 77(12):7034-7040.
20. Passini M.A., Wolf J.H. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J. Virol. 2001, 75(24):12382-12392.
21. Anson D.S., Fuller M. Rational development of a HIV-1 gene therapy vector. J. Gene Med. 2003, 5(10):829-838.
22. Koldej R., Cmielewski P., Stocker A., Parsons P.W., Anson D.S. Optimisation of a multipart immunodeficiency virus based vector system; control of infectivity and large-scale production. J. Gene Med. 2005, 7(11):1390-1399.
23. Wolfe J.H., Sands M. Murine mucopolysaccharidosis type VII: a model system for somatic gene therapy of the central nervous system. In Protocols for Gene Transfer in Neuroscience:Towards Gene Therapy of Neurologic Disorders 1996, 263-274. Wiley, New York. P.R. Lowenstein, L.W. Enquist (Eds.).
24. Glaser J.H., Sly W.S. Beta-glucuronidase deficiency mucopolysaccharidosis: methods for enzymatic diagnosis. J. Lab. Clin. Med. 1973, 82(6):959-977.
25. Leaback D.H., Walker P.G. Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase. Biochem. J. 1961, 78:151-156.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
27. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal. Biochem. 1973, 54:484-489.
28. Hopwood J.J., Harrison J.R. High-resolution electrophoresis of urinary glycosaminoglycans: an improved screening test for the mucopolysaccharidoses. Anal. Biochem. 1982, 1(119):120-127.
29. Turnbull J.E., Hopwood J.J., Gallagher J.T. Exosequencing of heparin sulphate/heparin saccharides using lysosomal enzymes. A Laboratory guide to glycoconjugate analysis 1997, 261-277. Birkauser Verlag, Basel. P. Jackson, J.T. Gallagher (Eds.).
30. Merril C.R., Dunau M.L., Goldman D. A rapid sensitive silver stain for polypeptides in polyacrylamide gels. Anal. Biochem. 1981, 1(110):201-207.
31. Anson D.S., McIntyre C., Thomas B., Koldej R., Ranieri E., Roberts A., Clements P., Dunning K., Byers S. Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. Genet. Vaccines Ther. 2007, 5(1).
32. Sferra T.J., Backstrom K., Wang C., Rennard R., Miller M., Hu Y. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. 2004, 10(3):478-491.
33. Vogler C., Sands M.S., Galvin N., Levy B., Thorpe C., Barker J., Sly W.S. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J. Inherit. Metab. Dis. 1998, 21(5):575-586.
34. Sands M.S., Wolfe J.H., Birkenmeier E.H., Barker J.E., Vogler C., Sly W.S., Okuyama T., Freeman B., Nicholes A., Muzyczka N., Chang P.L., Axelrod H.R. Gene therapy for murine mucopolysaccharidosis type VII. Neuromuscul. Disord. 1997, 7(5):352-360.
35. Sands M.S., Vogler C., Torrey A., Levy B., Gwynn B., Grubb J., Sly W.S., Birkenmeier E.H. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest. 1997, 99(7):1596-1605.
36. Hoenerhoff M.J., Strarost M.F., Ward J.M. Eosinophilic crystalline pneumonia as a major cause of death in 129S4/SvJae mice. Vet. Pathol. 2006, 43(5):682-688.
37. Bosch A., Perret E., Desmaris N., Heard J.M. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 2000, 1(1):63-70.
38. Cearley C.N., Wolf J.H. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 2007, 27(37):9928-9940.
39. Wang B., O'Malley T.M., Xu L., Vite C., Wang P., O'Donnell P.A., Ellinwood N.M., Haskins M.E., Ponder K.P. Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol. Genet. Metab. 2006, 87(1):8-21.
40. Boado R.J., Zhang Y., Zhang Y., Pardridge W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain-barrier. Biotechnol. Bioeng. 2007, 96(2):381-391.
41. Vogler C., Birkenmeier E.H., Sly W.S., Levy B., Pegors C., Kyle J.W., Beamer W.G. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase deficient mice. Am. J. Pathol. 1990, 136(1):207-217.
42. Daly T.M., Ohlemiller K.K., Roberts M.S., Vogler C.A., Sands M.S. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 2001, 8(17):1291-1298.
43. Elliger S.S., Elliger C.A., Lang C., Watson G.L. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol. Ther. 2002, 5(5):617-626.
44. Croyle M.A., Callahan S.M., Auricchio A., Schumer G., Linse K.D., Wilson J.M., Brunner L.J., Kobinger G.P. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 2004, 78(2):912-921.
45. Schiedner G., Hertel S., Johnston M., Dries V., van Rooijen N., Kohanek S. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol. Ther. 2003, 7(1):35-43.
46. Watson G.L., Sayles J.N., Chen C., Elliger S.S., Elliger C.A., Raju N.R., Kurtzman G.J., Podsakoff G.M. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther. 1998, 5(12):1642-1649.
47. Kyle J.W., Birkenmeier E.H., Gwynn B., Vogler C., Hoppe P.C., Hoffmann J.W., Sly W.S. Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase transgene. Proc. Natl Acad. Sci. USA 1990, 87(10):3914-3918.
48. Erlich S.S., McComb J.G., Hyman S., Weiss M.H. Ultrastructure of the orbital pathway for cerebrospinal fluid drainage in rabbits. J. Neuosurg. 1989, 70:926-931.
49. Hennig A.K., Levy B., Ogilvie J.M., Vogler C.A., Galvin N., Bassnett S., Sands M.S. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. 2003, 23(8):3302-3307.
50. Elliger S.S., Elliger C.A., Aguilar C.P., Raju N.R., Watson G.L. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther. 1999, 6(6):1175-1178.
51. Spencer B.J., Verma I.M. Targeted delivery of proteins across the blood-brain barrier. PNAS 2007, 104(18):7594-7599.